Clinical trials: Locally Advanced Angiosarcoma
Locally Advanced Angiosarcoma, Metastatic Angiosarcoma
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
This phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come…
- Conditions
- Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma
- Trial name
- NCT05026736
- Testing
- Quality-of-Life Assessment, Sintilimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Angiosarcoma of Skin
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
This is a single-arm study evaluating the efficacy of injecting Talimogene Laherparepvec T-VEC into Cutaneous Angiosarcoma tumors.
- Trial name
- NCT03921073
- Testing
- T-VEC
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy.
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT02048722
- Testing
- regorafenib
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Sarcoma, Epithelioid Sarcoma
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
- Conditions
- Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
- Trial name
- NCT03069378
- Testing
- Talimogene Laherparepvec (T-VEC), Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Angiosarcoma, Adult Epithelioid Sarcoma
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma.
- Conditions
- Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00245102
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- National Cancer Institute (NCI)